Navigation Links
ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
Date:9/23/2009

er on the milestones needed to build a strong, successful and profitable Company."

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015 Research and Markets ... "Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, ... offering. Video communication has been the topic of ... the United States and the Soviet Russia. ...
(Date:1/23/2015)... , Jan. 23, 2015  A new analysis of Centers ... 2015 enrollment data shows that 81 percent of seniors ... and extra discounts at certain pharmacies. The findings were ... pharmacy plans are now the foundation of Medicare Part ...
(Date:1/23/2015)... and DUBLIN , Jan. 23, 2015  Immune ... KRS Global Biotechnology, Inc. for the compounding, packaging and distributing ... shipment in the United States . ... Facility capable of compounding naltrexone tablets in various strengths for ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4
... Amira Pharmaceuticals, Inc. announced today that preclinical data from ... Journal of Pharmacology.   , ... The LPA1 receptor is part of the Phosphatidic ... a role in lung, kidney and skin fibrosis.  In particular, activation ...
... , SEATTLE and ATLANTA , May ... Elekta recently finalized a strategic partnership to launch ... for cancer patients. This unique, multi-year, multi-product collaboration covers the ... and delivery to workflow and connectivity – and ...
Cached Medicine Technology:Anti-Fibrotic Data from Amira Pharmaceuticals' LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology 2Swedish Cancer Institute and Elekta Launch Renewed Partnership Agreement to Continue the Flow of World-Class Technology, Services to Cancer Patients in the Pacific Northwest and Beyond 2Swedish Cancer Institute and Elekta Launch Renewed Partnership Agreement to Continue the Flow of World-Class Technology, Services to Cancer Patients in the Pacific Northwest and Beyond 3Swedish Cancer Institute and Elekta Launch Renewed Partnership Agreement to Continue the Flow of World-Class Technology, Services to Cancer Patients in the Pacific Northwest and Beyond 4Swedish Cancer Institute and Elekta Launch Renewed Partnership Agreement to Continue the Flow of World-Class Technology, Services to Cancer Patients in the Pacific Northwest and Beyond 5Swedish Cancer Institute and Elekta Launch Renewed Partnership Agreement to Continue the Flow of World-Class Technology, Services to Cancer Patients in the Pacific Northwest and Beyond 6
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has been a leading ... showing its latest designs of wedding dresses and launching a ... CEO, all the fresh new products are designed for 2015, ... 80% off. All the clothes from LunaDress follow up with ...
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... January 23, 2015 Recently, Weddingshe.com has added ... and has announced its highest annual revenues in the past ... its popular glamorous wedding dresses. , According to the sales ... wedding dress promotions for them in 2015. This point can ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... DIEGO, May 11 , WHAT: 211 San Diego executives ... organization is undertaking to make 211 a nationwide service, ... during, times of need, ... resources at Join Our Journey event. 211 San Diego also will, ...
... from Regence BlueCross BlueShield President and CEO Mark Ganz. ... of private-sector health industry leaders to decrease the U.S.,s annual ... $2 trillion over the next ten years:"I support the health ... nation. We are a country that spends more than ...
... Interfere with Prescribed TherapiesSACRAMENTO, Calif., May 11 The ... a national network of over 250 physicians with the ... approved medical treatments and therapies, today cited a recent ... a large number of physicians believe insurance companies are ...
... GAINESVILLE, Fla. University of Florida researchers have learned more ... may reveal as much about the human immune system as ... , In findings to be published this week in the ... Academy of Sciences , scientists describe how they looked at ...
... Healthcare Realty Trust Incorporated (NYSE: HR ) ... ended March 31, 2009. This dividend, in the amount ... to shareholders of record on May 22, 2009. The ... cash flows from operations determined in accordance with GAAP. ...
... incorrect but worrying findings rises 50 percent by the 14th ... The more cancer screening tests you undergo, the higher your ... , While that conclusion may seem like common sense, ... the authors of a study in the May/June issue of ...
Cached Medicine News:Health News:211 San Diego Provides Support to San Diegans in Times of Crisis 2Health News:Regence Optimistic About Health Industry Leaders' Pledge to Cut Health Care Costs 2Health News:Alliance for Patient Access Wants Health Care Code of Conduct 2Health News:Scientists discover how smallpox may derail human immune system 2Health News:Healthcare Realty Trust Announces First Quarter Dividend 2Health News:Healthcare Realty Trust Announces First Quarter Dividend 3Health News:Healthcare Realty Trust Announces First Quarter Dividend 4Health News:More Cancer Tests Mean More False-Positive Results 2Health News:More Cancer Tests Mean More False-Positive Results 3
... is a single-use device that produces ... thermal spread and vapor sealing of ... can be used for resection of ... It is also an excellent tool ...
... PK Plasma V is a single ... tissue removal with minimal thermal spread and ... adenoma in the treatment of BPH, without ... vaporization of the prostate (PKVP), the Plasma-V ...
Medium Clip Appliers. American-made stainless steel, 6" long, curved tip. For use with VE-6-25 and VE-6-10 titanium surgical clips only....
Li Brand™ Surgical Hemostat. ("dissecting clamp") For NSV and other procedures....
Medicine Products: